Our client, a leading global biopharma, wanted monitor how biopharma is investing and operating in Digital Health across their value chain, to better support its own Digital Health portfolio strategy.
Galen Growth mapped out the Digital Health partnerships of their top 25 competitors, across 15 countries and two therapeutic areas. We then c-developed a relevance scoring methodology, driven by our proprietary venture signals which enabled the prioritising of 500+ relevant ventures for consideration as a partner for our client.
| Number of countries | 15 |
| Number of Key TAs analysed | 2 |
| Number of ventures screened | 500+ |
| Number of ventures shortlisted | 50 |
Contact us to explore how your organisation can fast track its Digital Health strategy with Galen Growth
